Pharmafile Logo
Pharmafocus logo
Advanced Search

Cephalon

Showing 15 posts of 19 posts found.

teva_copy

Teva denies wrongdoing in Cephalon pay-to-delay deal hearing

March 14, 2018
Research and Development, Sales and Marketing Cephalon, Pay to delay, Provogil, Teva, pay-to-delay, pharma

Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its …

News
mylan

Mylan pays $96.5 million to settle pay-for-delay case

February 7, 2017
Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust

Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …

News

Teva settles generic ‘pay-to-delay’ case for $1.2 billion

May 29, 2015
Sales and Marketing Cephalon, FTC, Teva, modafinil, provigil

Teva Pharmaceuticals has agreed to a $1.2 billion settlement for paying generic drug makers to delay challenging the patent for …

News
Teva image

Teva faces $512m fine in generic Provigil row

April 22, 2015
Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil

Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …

News
Pfizer picture

Pfizer recalls oral contraceptive for packaging errors

February 2, 2012
Manufacturing and Production Akrimax, Bedford, Cephalon, Lo/Ovral-28, Pfizer, Teva

Pfizer has been forced to recall a large volume of oral contraceptive packs distributed in the US market because a …

News
Cephalon

Teva’s Cephalon acquisition could be delayed

June 15, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Cephalon, Teva

The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month. …

News
Cephalon

Cephalon accepts Teva’s $6.8 billion white knight bid

May 3, 2011
Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics

Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …

News
Cephalon

Valeant makes $5.7 billion hostile bid for Cephalon

March 31, 2011
Research and Development, Sales and Marketing Cephalon, Valeant

Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …

News

Cephalon buys Gemin X for $225 million

March 24, 2011
Research and Development Cephalon, lung cancer

Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …

News

Allergan marketing breaches discredited industry

March 22, 2011
Medical Communications Allergan, Cephalon, PMCPA

Allergan, the manufacturer of Botox, has been censured for several breaches of the ABPI Code of Practice. The PMCPA watchdog …

News
ABPI Code of Practice

Cephalon in trouble over party spirit

February 11, 2011
Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation

Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …

News

Cephalon’s Paul Harmon joins IPHA board

January 10, 2011
Sales and Marketing Cephalon, IPHA, Paul Harmon, appointment, sales and marketing

Cephalon’s Paul Harmon has been elected to the prescription medicines division strategy board of Irish pharma association IPHA, a role …

Appointment

Cephalon chairman takes leave of absence

September 2, 2010
Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing

Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …

Appointment

Cephalon completes acquisition of generics firm Mepha

April 16, 2010
Sales and Marketing Cephalon, generics

Specialist pharmaceutical company Cephalon has completed the $615.4 million acquisition of Mepha. Based in Switzerland, Mepha specialises in using reformulation …

News

Cephalon to develop new class of cancer drug

March 19, 2010
Research and Development CRT, Cancer, Cancer Research UK, Cephalon

Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class …

News

Latest content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023